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Background: The present study aimed to evaluate the efficacy of local lidocaine injections into the myofascial
trigger points (TPs) located at the pericranial muscles in patients with episodic tension-type headache (ETTH).
Methods: The study included 108 patients with frequent ETTH that were randomized into 4 groups. One injection
of saline (NaCl 0.9%) was administered to group 1 (n = 27), 1 injection of lidocaine (0.5%) was administered to
group 2 (n = 27), group 3 (n = 27) received 5 injections of saline (NaCl 0.9%), and group 4 (n = 27) received 5
injections of lidocaine (0.5%); on alternate days 2 mL for each muscle was injected into the frontal, temporal,
masseter, sternocleidomastoid, semispinalis capitis, trapezius and splenius capitis muscles bilaterally. The frequency
of painful days per month (FPD) and the patients’ visual analogue scales (VAS) were evaluated before treatment,
and 2, 4 and 6 months after treatment.
Results: Mean age of the patients was 36.28 ± 9.41 years (range: 18–54 years). FPD scores improved significantly in
group 2, 3 and 4 at 2 months posttreatment compared to pre- treatment (all P < 0.05), and also VAS scores
improved significantly in group 2 and 4 at 2 months posttreatment (P < 0.05) but this improvement insisted at the
6 month only in group 4. Group 2 had better VAS and FPD than group 1 only at 2. and 4. months after treatment
(for VAS P < 0.0121, P = 0.0232; for FPD P = 0.0003, P = 0.0004, respectively). Group 4 had better scores than group 3
at the 2., 4. and 6. months after treatment in both parameters (all P < 0.05). Group 2 had better scores than group 1
in FPD at the 2. and 4. months posttreatment (P = 0.0003, P = 0.0004, respectively), but not at the 6. month.
Conclusion: Local lidocaine injections into the myofascial TPs located in the pericranial muscles could be
considered as an effective alternative treatment for ETTH.
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Headache is one of the most common symptoms in the
general population. It is important to emphasize that
headache can be a symptom of serious pathology and can
be due to many etiologies [1]. According to population-
based studies, the annual prevalence rates are 38.3% for
episodic tension-type headache (ETTH) and 2.2% for
chronic tension-type headache (CTTH) [2]. The preva-
lence of tension-type headache (TTH) is highest between
the 2nd and 5th decades of life, peaking between 30 and
40 years of age [3,4].* Correspondence: dromerkaradas@hotmail.com
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in any medium, provided the original work is pIt remains unclear if TTH is caused by peripheral mech-
anisms or by the central nervous system (CNS) [5,6]. One
reported hypothesis is that altered pain modulation due to
nociceptive stimuli arising from pericranial myofascial tis-
sues may cause sensitization in the trigeminal nucleus,
thalamus, or somatosensory cortex [7]. Another study
reported a decrease in the gray matter volume in patients
with CTTH, suggesting that this condition is the result of
central sensitization caused by stimuli arising in pericra-
nial myofascial tissues [8]. Peripheral mechanisms also
play a major role in TTH. Prolonged peripheral nocicep-
tive input has been reported to increase sensitization to
peripheral pain via sensitization of the central mecha-
nisms, resulting as CTTH [9,10].an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Patient demographics
Group 1 Group 2 Group 3 Group 4
n (Male/Female) 8/19 7/20 9/18 8/19
Age (years) 36,1 ± 9,7 37,03 ± 8,1 35,96 ± 9,5 36,03 ± 10,6
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tonin gene-related peptide (CGRP) also play a role in
myofascial pain [11]. A placebo-controlled study by Jensen
and Olsen reported that experimental tooth clenching for
30 minutes triggered TTH in patients with CTTH or
ETTH. Their results showed that 69% of the patients de-
veloped TTH within 24 hours, versus 17% of the control
group. Pain tolerance decreased in patients that developed
TTH, but no change was observed in the other partici-
pants. Their results also suggested that insufficient activa-
tion of the antinociceptive system in the patients with
TTH and peripheral mechanisms might play a role in the
pathogenesis of TTH by triggering the central mecha-
nisms [12]. Hu et al. [13] reported that neurons in the tri-
geminal nucleus (located in the brainstem) were sensitized
via stimulation of craniofacial muscle afferents.Table 2 Comparison of the data of visual analogue scale belo
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Comparison G1 vs G2
p value a 0.0121




Comparison G1 vs G2
p value a 0.0232




Comparison G1 vs G2
p value a 0.4987
N: Number of patients, SD: Standard deviation, * One-way Analysis of Variance (ANO
ANOVA is <0.05, p values of between groups (G1,G2,G3 and G4) are compared.Treatment of TTH includes both acute and prophylactic
treatments. Analgesics are used for the acute treatment of
TTH, whereas antidepressants are used for prophylaxis.
These drugs’ side effects and drug interactions must be
taken into consideration during such treatment [14]. Non-
pharmacological pain management alternatives may also
be considered; however, current data have not proven that
they are efficacious [15].
The aim of the present study was to evaluate the effi-
cacy of local lidocaine injections into the myofascial TPs
at the pericranial muscles, to regulate the antinociceptive
system in the treatment of frequent ETTH.
Methods
The study included patients aged between 18 and 65 years
that were diagnosed with frequent ETTH according to
the criteria published in 2004 by the International Head-
ache Society (IHS) [16], that had normal physical and
neurological examination results, and had headache less
than 15 days per month during the previous 6 months.
All patients were evaluated ragarding the other causes
of headache and patients who had headache with anging to all groups before and after treatment
G2 G3 G4 * p value









G1 vs G3 G2 vs G4 G3 vs G4
a 0.4431 a 0.0037 a <0.0001




G1 vs G3 G2 vs G4 G3 vs G4
a 0.7527 a 0.0075 a <0.0001




G1 vs G3 G2 vs G4 G3 vs G4
a 0.7533 a 0.0007 a 0.0002
VA), a Unpaired t test. VAS: Visual Analogue Scale. If p value obtained by
Table 3 Comparison of the frequency of painful days belonging to all groups before and after treatment
Group 1 Group 2 Group 3 Group 4 * p
FPD before treatment N 27 27 27 27 0.9272
Mean 11,1 10,8 11,0 11,0
SD 1,7 1,8 1,6 2,2
Minimum 8 7 8 7
Maximum 14 14 13 14
FPD for 2 months after treatment Mean 10,4 8,4 9,9 6,6 <0.0001
SD 1,2 2,4 1,3 2,2
Minimum 9 4 7 2
Maximum 12 13 12 10
Comparison G1 vs G2 G1 vs G3 G2 vs G4 G3 vs G4
p value a 0.0003 a 0.1708 a 0.0071 a <0.0001
FPD for 4 months after treatment Mean 10,9 8,8 10,7 7,6 <0.0001
SD 1,6 2,3 1,6 1,9
Minimum 8 5 8 4
Maximum 14 13 14 11
Comparison G1 vs G2 G1 vs G3 G2 vs G4 G3 vs G4
p value a 0.0004 a 0.8007 a 0.0466 a <0.0001
FPD for 6 months after treatment Mean 11,1 10,3 10,9 7,9 <0.0001
SD 1,4 2,4 1,5 2,0
Minimum 9 6 8 4
Maximum 14 15 14 11
Comparison G1 vs G2 G1 vs G3 G2 vs G4 G3 vs G4
p value a 0.1506 a 0.7068 a 0.0003 a <0.0001
N: Number of patients, SD: Standard deviation, * One-way Analysis of Variance (ANOVA), FPD: Frequency of painful days per month. If p value obtained by ANOVA
is <0.05, p values of between groups (G1,G2,G3 and G4) are compared.
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Our study was approved by Local Ethics Committee
and informed consent forms were obtained from all
participants.
Exclusion criteria:
 Patients responding to medical treatment
 Patients using more than 15 doses of analgesics in a
month
 Patients who received botulinum toxin type A
(BoNT-A) therapy
 Pregnant women
 Patients with known allergies against local
anesthetics
 Patients with a history of malignancy
 Patients who had a history of cervical and cranial
surgery
 Patients who had received non-pharmacological
therapy for the last 6 months
 Patients with anemia and bleeding diathesis
 Patients with major psychiatric disorders (major
depression etc.) Patients who used antipsychotic, antidepressant and
antiepileptic drugs within the previous 3 months
 Patients with neuromuscular dysfunction
 Patients with uncontrolled hypertension
 Patients with hypothyroidism or hyperthyridism
Whole blood count, routine biochemistry, and thyroid
function tests were performed, and vitamin B-12, folate,
and ferritin levels were measured in each patient to ex-
clude possible secondary causes of frequent ETTH. Com-
puted tomography (CT) or magnetic resonance imaging
(MRI) were performed when considered to be necessary.
This was a double-blind placebo controlled randomized
study. Patients were randomly assigned into four groups.
The study medication was prepared by a registered nurse.
The study medication was delivered to the injecting phys-
ician in identical appearing syringes by a different nurse.
Each syringes contained an identical amount of solution.
Evaluations and injections were performed by separate
physicians. Neither the physician nor the patient knew
which treatment to be administered. The evaluator was
blind to treatment groups. The study protocol was ap-
Figure 1 An illustration of all groups, the distribution of values
for visual analogue scale (VAS): (A) before treatment and (B) 2
months after treatment.
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signed informed consent forms. In all, 108 patients were
included to the study, following implementation of inclu-
sion and exclusion criterias. Pain severity in patients was
evaluated using the visual analogue scale (VAS) and the
frequency of painful days per month (FPD) were recorded
before the treatment.
Procedure
Patients were randomly divided into 4 groups. One injec-
tion of saline (NaCl 0.9%) was administered to group 1
(n = 27), 1 injection of lidocaine (0.5%) was administered
to group 2 (n = 27), group 3 (n = 27) received 5 injections
of saline (NaCl 0.9%), and group 4 (n = 27) received 5Figure 2 Graph showing the frequency of painful days before
and after treatment in all groups.injections of lidocaine (0.5%): on alternate days 2 mL for
each muscle was injected into the frontal, temporal, mas-
seter, sternocleidomastoid, semispinalis capitis, trapezius
and splenius capitis muscles bilaterally. Injections were
perfomed into the trigger points of the muscles. We
detected pericranial myofascial trigger points by making
small circular movements, applying deep finger pressure
(finger tipping) on the surface of the muscles with system-
atic palpation as explained in Travel & Simons manual
[17]. All the patients have headache bilaterally, and
myofascial trigger points were detected bilaterally in all
patients. Lidocaine injections were performed to same
muscles (injections were made to myofascial trigger points
of the muscles that have dominant areas with pain) and
with standard doses. Applications in repetetive injections
were made to the same trigger points.
The patients’ VAS and FPD were evaluated before treat-
ment, and 2, 4, and 6 months after treatment. The efficacy
of the injections was evaluated 2, 4, and 6 months after
treatment by a physician (different than the one that ad-
ministered the injections) blinded to patients group.
Statistical analysis was performed using SPSS software
for Windows, version 15.0. Mann Whitney U test was
used for non-parametric unpaired values with a group
number equal to 2. For parametric unpaired data with a
group number equal to 2, the unpaired t-test was used. In
nonparametric unpaired data with more than 2 groups,
the Kruskal Wallis test was used. In parametric data with
more than 2 groups, the one way analysis of variance
(ANOVA) was used.
Results
The present study included 108 patients (32 male, 76 fe-
male). The mean age of the patients was 36.28 ± 9.41 years
(range: 18–54 years). Demographic characteristics of the
patients are summarized in Table 1. There weren’t any dif-
ferences in age or gender between the groups (P > 0.05).
As observed in Table 2: the mean VAS scores during pre-
treatment and at the 2., 4. and 6. month in group 1 were
found to be 71.5 ± 7.6, 68.0 ± 9.0, 69.8 ± 6.6 and 70.2 ± 6.7,
in group 2: 70.4 ± 8.4, 59.8 ± 13.6, 64.1 ± 10.9 and 68.9 ±
7.3, in group 3: 70.7 ± 6.9, 66.1 ± 8.6, 69.3 ± 6.3 and 69.2 ±
6.2 and in group 4: 71.1 ± 10.2, 48.5 ± 13.7, 55.6 ± 11.5 and
58.7 ± 12.7, respectively.
All the groups were similar in terms of VAS and FPD
before treatment (all P > 0.05) (Table 2 and Table 3 and
Figures 1A and 2). FPD scores improved significantly in
group 2, 3 and 4 at the 2. month posttreatment when
compared with pretreatment (all P < 0.05), and also VAS
scores improved significantly in group 2 and 4 at the 2.
month posttreatment (P < 0.05) but this improvement
insisted at the 6. month only in group 4 (Table 4 and
Figures 1B, 2 and 3). Group 2 had better VAS and FPD
scores than group 1 only at the 2. and 4. months after
Table 4 Visual analogue scale and frequency of painful days per month scores before and after treatment in all groups
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BT: Before treatment, AT: After treatment, VAS: Visual analogue scale, FPD: frequency of painful days per month, * p Value for Repeated Measures ANOVA (Analysis of Variance) with post test, ª Post tests were not



















Figure 3 An illustration of all groups, the distribution of values
for visual analogue scale (VAS) for (A) 4 month after treatment
and (B) 6 months after treatment.
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group 3 at the 2., 4. and 6. months after treatment in both
parameters (all P < 0.05) (Figures 1B, 2 and 3).
When the FPD in group 4 were compared pre- and
posttreatment (2, 4 and 6 mounth), all posttreatment FPD
scores compared to pretreatment scores was significantly
lower (Figure 4).
No serious side effects leading to the termination of the
treatment were observed; other side effects are shown in
Table 5.Figure 4 Comparison of the frequency of painful days before
and after treatment belonging to the group received injection
of lidocaine hydrochloride 5 times. A significant decrease in the
frequency of painful days after treatment (2, 4 and 6 month)
compared to pre-treatment was observed P < 0.001). 2., 4. and 6.
Months after the treatment, there was no difference between the
frequency of painful days (P > 0.005).Discussion
The present study demonstrated clinical benefit among
lidocain treated frequent ETTH patients. The results
showed that 5 lidocaine injections on alternate days signifi-
cantly reduced both the frequency and severity of pain at
the 2., 4. and 6. months post treatment, as compared to
the placebo; in addition, patients with frequent ETTH
responded better to repeated lidocaine injection treatment.
Most commonly, frequent TTH affects individuals be-
tween the ages of 30 and 40 years [3,4]. Mean age of the
patients in the present study was 36.7 years. It remains
unclear if the primary origin of TTH is peripheral or
central; however, it is conceivable that both peripheral
and central mechanisms play a role in TTH. In order to
re-establish pain control, it seems that it is possible to
regulate the central response by controlling prolonged
and increased peripheral inputs. The use of lidocaine in-
jections to control pain via regulating the peripheral
pathways that play a role in the development of TTH
supports this opinion.
Use of local anesthetics at the appropriate concentra-
tions blocks nerve conduction. They exert their effects not
only on nerve fibers (axons and dendrites), but also on the
nerve body, myocardium, skeletal muscles, smooth mus-
cles, and on other excitable cells by reversibly blocking
the transmission of depolarization waves. Additionally,
they temporarily block painful signal transmission to the
central nervous system [18]. Depending on the concentra-
tion, local anesthetics decrease Na influx by blocking Na
channels, and decrease the rate of depolarization in nerve
fibers and other excitable cells. Finally, local anesthetics in-
hibit excitable cells’ ability to spontaneously discharge [19].
Recent research has highlighted the importance of the
TPs in such painful conditions as primary headache disor-
ders and myofascial pain syndrome. TPs might play a role
in the perception of the severity of pain by sensitizing the
neurons of the trigeminal caudal nucleus, which receive
input from cephalic blood vessels and pericranial muscles
[3,20]. It was reported that the primary mechanism in the
development of TTH is sensitization of the central path-
ways due to prolonged nociceptive inputs that arise in the
pericranial myofascial muscles [20,21]. High concentra-
tions of bradykinin, CGRP, substance P, TNF-α, IL-1b,
serotonin, and norepinephrine in the TPs located in the
pericranial myofascial tissues have been shown histo-
pathologically. These mediators are suggested to play a
role in the pathogenesis of TTH [22]. Localization of theTable 5 The frequency of side effects
Side Effects Group 1 Group 2 Group 3 Group 4
Pain at injection area 1 1 1 1
Dizziness 1 0 1 1
Servical muscle spasm 1 0 0 1
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however, the trapezius, posterior cervical paraspinal, sub-
occipital, and sternocleidomastoid muscles are the most
common muscle groups in which TPs are located [23].
Stretch, TENS, injection therapies , and dry needling have
all shown benefit [24]. Saline injections are also known to
be effective [25] and as we used saline at the placebo
group, we also underline that lidocaine injections are
more effective than saline injections.
The pain-relieving effect of local anesthetic injection
into the TPs may be due to a mechanism involving a de-
crease in mediators that cause algesia, desensitization of
free-nerve endings, inhibition of the spread of pain within
the muscles, and then suppression of the perception of
prolonged pain in peripheral tissues. Repeated injections
might also increase this effect and provide long-lasting
pain relief. In the present study we used 5 lidocaine injec-
tions in group 4 to increase its lidocaine’s efficacy by sup-
pressing the perception of prolonged pain. Decreases in
the frequency of pain and VAS scores recorded in group 4
posttreatment at the 2., 4. and 6. months showed that the
treatment protocol was successful.
Venancio et al. [23] compared the efficacy of lidocaine,
corticosteroid, and dry-needle injections into the myo-
fascial TPs and reported that lidocaine was effective in the
treatment of headache. In another study Venancio et al.
[26] compared BoNTA, lidocaine, and dry-needle injec-
tion into the myofascial TPs and suggested that lidocaine
is a cost-effective treatment option for headache. Calandre
et al. [27] evaluated 12 patients with cluster headache
(4 episodic and 8 chronic). They administered mepi-
vacaine (3%) to 6 patients at the beginning of their attacks
and 5 of the patients (85%) had no complaints within mi-
nutes. Prophylactic treatment was given to 7 patients,
which prevented attacks in 6 of the patients (86%). Add-
itionally, in the 8 patients with chronic cluster headache
they observed that the frequency of attacks decreased
more than 50%, and that the severity and duration of at-
tacks decreased in 7 of the patients.
Giamberardino et al. showed the effects of local therapy
of active myofascial trigger points on migraine symptoms
in 87 migraine patients [28]. Tfelt-Hansen et al. injected
1.5% lidocaine and saline to the trigger points of 50 acute
migraine patients. 28 patients gave response to therapy
but no significant difference was present between two
groups [29]. Garcia-Levia et al. [30] injected 10 mg of
ropivacaine into the myofascial TPs in 52 patients with
migraine. The severity of pain decreased by more than
50% in 9 patients and by 11%-49% in 19 patients. They
reported that post-treatment 8 out of 30 patients with
chronic migraine had episodic migraine. Martin Herrero
et al. reported that referred pain induced by myofascial
trigger points (MTP) and sleep disorders can be factors
that contribute to chronic tension-type headache [31].Alonso Blanco et al. reported that active trigger points
(TrPs) in neck and shoulder muscles contribute to ten-
sion-type headache [32]. In the present study repeated
lidocaine injections successfully controlled prolonged and
increased peripheral pain inputs, and resulted in pro-
longed pain control by re-establishing the central response
to the pain; these results are in agreement with those of
other studies [22-28].
There may be shifting between the sub-groups of TTH.
Patients with frequent ETTH are at risk of developing
CTTH. The primary reason for shifting from ETTH to
CTTH is analgesic overuse [3]. Patients that were young
and female, and had no vocational education, familial dis-
position, a high work load, and frequent TTH at baseline
had an increased risk of migraine [33]. As such, control-
ling ETTH before it transforms to CTTH or migraine
is essential.
The main limitations of the present study are the small
number of patients included and the short duration of
follow-up; however, the data obtained have important im-
plications for the treatment of frequent ETTH.
Conclusions
As a result, post-treatment results of the lidocain injected
groups were different from the pretreatment and the treat-
ment found to be effective. According to the results, appli-
cation of repeated lidocain injection is said to be an
effective treatment approach that provides long-lasting
state of well being. For putting out the efficacy of lido-
cain injections in frequent ETTH exactly, randomized,
placebo-controlled and long term follow up studies with
repetetive and with different doses of lidocain injections
are needed.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KO has made the study design and injections were made by him. GHL has
followed up and recorded the patients data, and wrote the manuscript. İLE
has checked out the writing format and stastistical analysis. All authors read
and approved the final manuscript.
Disclosures
Financial disclosure statements have been obtained, and no conflicts of
interest have been reported by the authors or by any individuals in control
of the content of this article.
Author details
1Neurology Service, Erzincan Military Hospital, Erzincan, Turkey. 2Department
of Neurology, Kartal Education and Research Hospital, Istanbul, Turkey.
3Department of Neurology, Ankara Education and Research Hospital, Ankara,
Turkey.
Received: 1 March 2013 Accepted: 6 May 2013
Published: 22 May 2013
References
1. Inan LE (2003) Gerilim tip baş ağrıları. Turkiye Klinikleri J Neurol-Special
Topics 1(2):127–132
Karadaş et al. The Journal of Headache and Pain 2013, 14:44 Page 8 of 8
http://www.thejournalofheadacheandpain.com/content/14/1/442. Schwartz BS, Stewart WF, Simon D, Lipton RB (1998) Epidemiology of
tension-type headache. JAMA 279(5):381–383
3. Silberstein SD, Lipton RB, Goadsby PJ (2002) Tension-Type Headache:
Diagnosis and treatment. In: Clinical Practice of Headache, 2nd edn. Martin
Dunitz, Oxford, pp 113–128
4. Lipton RB, Hamelsky SW (2001) Epidemiology and impact of headache. In:
Silberstein SD, Lipton RB, Dalessio DJ (eds) Wolff’s Headache and Other
Head Pain, 7th edn. Ny. Oxford University Press, New York, pp 85–107
5. Olesen J, Langemark M (1988) Mechanisms of tension headache. A
speculativehypothesis. In: Olesen J, Edvinsson L (eds) Basic mechanisms of
headache. Elsevier, Amsterdam, pp 457–461
6. Jensen K (1990) Quantification of tenderness by palpitation and use of
pressure algometers. In: Fricton JR, Awad E (eds) Adv Pain Res Ther, vol 17.
Raven, New York, pp 165–181
7. Bendtsen L, Schoenen J (2005) Synthesis of tension-type headache
mechanisms. In: Olesen J, Goadsby PJ, Ramadan N et al (eds) The
Headaches, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 677–681
8. Schmidt-Wilcke T, Leinisch E, Straube A, Kämpfe N, Draganski B, Diener HC,
Bogdahn U, May A (2005) Gray matter decrease in patients with chronic
tension type headache. Neurology 65(9):1483–1486
9. Buchgreitz L, Lyngberg AC, Bendtsen L, Jensen R (2007) Increased
prevalence of tension-type headache over a 12-year period is related to
increased pain sensitivity. A population study. Cephalalgia 27(2):145–152
10. Mense S (1993) Nociception from skeletal muscle in relation to clinical
muscle pain. Pain 54(3):241–289
11. Schmidt RF (1993) Sensitization of peripheral nocisensors in muscle. In:
Olesen J, Schoenen J (eds) Tension-type headache: classification,
mechanisms and treatment. Raven, New York, pp 47–59
12. Jensen R, Olesen J (1996) Initiating mechanisms of experimentally induced
tension-type headache. Cephalalgia 16(3):175–182
13. Hu JW, Sessle BJ, Raboisson P, Dallel R, Woda A (1992) Stimulation of
craniofacial muscle afferents induces prolonged facilitatory effects in
trigeminal nociceptive brain-stem neurones. Pain 48(1):53–60
14. Zissis NP, Harmoussi S, Vlaikidis N, Mitsikostas D, Thomaidis T, Georgiadis G,
Karageorgiou K (2007) A randomized, double-blind, placebo-controlled
study of venlafaxine XR in out-patients with tension-type headache.
Cephalalgia 27(4):315–324
15. Silver N (2007) Headache (chronic tension-type). Am Fam Physician
76(1):114–116
16. Headache Classification Subcommittee of the International Headache
Society (2004) The International Classification of Headache Disorders: 2nd
edition. Cephalalgia 24(suppl1):16–22
17. Jaeger B (1999) In: Simons DG, Travell JG, Simons LS (eds) Head and Neck
Pain, Travell & Simons’Myofascial pain and dysfunction the triger point
manual, IIth edn. Lippincott Williams&Wilkins, Pennsylvania, pp 237–484
18. Kayaalp O (2002) Lokal Anestezikler: in Kayaalp O (ed): Kayalalp Rasyonel
Tedavi Yönünden Tıbbi Farmakoloji, ed 10. Ankara, Hacettepe-TAŞ,
pp 792–806
19. Catterall WA, Kenneth M (2006) local anesthetics. In: Brunton LL, Lazo JS,
Parker KKL (eds) Goodman & Gilman's the pharmacological basis of
therapeutics, 11th edn. The Mcgraw-hill Mompanies Inc, Texas, pp 241–251
20. Bendtsen L (2000) Central sensitization in tension-type headache-possible
pathophysiological mechanisms. Cephalalgia 20(5):486–508
21. Jensen R (2003) Peripheral and central mechanisms in tension-type
headache: an update. Cephalalgia 23(Suppl 1):49–52
22. Shah JP, Phillips TM, Danoff JV, Gerber LH (2005) An in vivo microanalytical
technique for measuring the local biochemical milieu of human skeletal
muscle. J Appl Physiol 99(5):1977–1984
23. Venâncio Rde A, Alencar FG, Zamperini C (2008) Different substances and
dry-needling injections in patients with myofascial pain and headaches.
Cranio 26(2):96–103
24. Huguenin KL (2004) Myofascial trigger points: the current evidence. Phys
Ther Sport 5(1):2–12
25. Giamberardino MA, Affaitati G, Fabrizio A, Costantini R (2011) Myofascial
pain syndromes and their evaluation. Best Pract Res Clin Rheumatol
25(2):185–198
26. Venancio Rde A, Alencar FG Jr, Zamperini C (2009) Botulinum toxin,
lidocaine, and dry-needling injections in patients with myofascial pain and
headaches. Cranio 27(1):46–5327. Calandre EP, Hidalgo J, Garcia-Leiva JM, Rico-Villademoros F, Delgado-
Rodriguez A (2008) Myofascial trigger points in cluster headache patients: a
case series. Head Face Med 4:32
28. Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R, Di Ianni
L, Lapenna D, Mezzetti A (2007) Contribution of myofascial trigger points to
migraine symptoms. J Pain 8(11):869–878
29. Tfelt-Hansen P, Olesen J, Lous I (1980) Lignocaine versus saline in migraine
pain. Lancet 1(8178):1140
30. García-Leiva JM, Hidalgo J, Rico-Villademoros F, Moreno V, Calandre EP
(2007) Effectiveness of ropivacaine trigger points inactivation in the
prophylactic management of patients with severe migraine. Pain Med
8(1):65–70
31. Martín-Herrero C, de Souza DP R, Alburquerque-Sendín F, Ortega-Santiago
R, Fernández-de-Las-Peñas C (2012) Myofascial trigger points, pain, disability
and quality of sleep in patients with chronic tension-type headache: a pilot
study. Rev Neurol 55(4):193–199
32. Alonso-Blanco C, de-la-Llave-Rincón AI, Fernández-de-las-Peñas C (2012)
Muscle trigger point therapy in tension-type headache. Expert Rev
Neurother 12(3):315–322
33. Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R (2005) Incidence of
primary headache: a Danish epidemiologic follow-up study. Am J Epidemiol
161(11):1066–1073
doi:10.1186/1129-2377-14-44
Cite this article as: Karadaş et al.: Lidocaine injection of pericranial
myofascial trigger points in the treatment of frequent episodic tension-
type headache. The Journal of Headache and Pain 2013 14:44.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
